Key Reason

Explanation

Lack of Standardized Guidelines

No universal guidelines dictate when or how often MRD testing should be done in myeloma care. Some doctors use MRD results to guide treatment, while others don’t consider it essential for decision-making.

Unclear Impact on Long-Term Outcomes

While MRD negativity often correlates with a longer time in remission, it doesn’t always predict long-term survival. Some specialists are cautious about using MRD results to adjust treatment without clear evidence that it improves overall survival.

Different Testing Methods

MRD can be tested using various methods (e.g., flow cytometry, next-generation sequencing), producing different results. Disagreements arise over which method is most reliable or how sensitive the test should be.

Treatment Adjustment Debate

Some specialists believe MRD negativity could justify stopping or reducing treatment to minimize side effects. Others argue that patients should stay on treatment regardless of MRD status due to the risk of relapse.

Cost and Accessibility

MRD testing can be expensive and may not be covered by all insurance plans. This makes some doctors hesitant to recommend it, especially if they feel it won’t change the patient’s care plan.

Patient Preferences

Some patients want to know their MRD status for peace of mind, while others prefer not to focus on it. Specialists may differ in how much they weigh patient preference when deciding whether to order MRD testing.